secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2022-06-29T23:59:59+00:00
Accession:  0001493152-22-018038
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics updates clinical milestones; plans US re-submission and Phase I/IIa trial in Germany by Q3 2022
--------------------------------------------------------------------------------

- Company completing requirements to answer regulatory questions and begin US re-submission process.
- Submitting filing in Europe to commence Phase I/IIa trial at a major CRO site in Germany anticipated to start Q3 2022.
- Further updates to clinical development schedule to be provided as it becomes clearer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000149315222018038/0001493152-22-018038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000149315222018038/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-018038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer